Market Performance - Major A-share indices collectively surged, with the Shenzhen Component Index and ChiNext Index reaching new highs for the phase [1] - As of the close, the Shanghai Composite Index rose by 1.65% to 3875 points, the Shenzhen Component Index increased by 3.36% to a new high since July 2022, and the ChiNext Index climbed 5.15%, marking its highest since January 2022 [1] - The STAR 50 Index also saw a significant increase of 5.32% [1] Trading Volume - The total trading volume for the day was 2.46 trillion yuan, an increase of 460.6 billion yuan compared to the previous trading day, with over 4200 stocks rising across the market [1] Sector Performance - The CPO concept stocks experienced a resurgence, with companies like Zhongji Xuchuang, Tianfu Communication, and Xinyi Sheng seeing gains of over 10% [1] - The PCB and electronic components sectors witnessed a surge, with stocks such as Jinxin Nuo, Hudian Shares, and Dazhu Laser hitting the daily limit [1] - The semiconductor sector strengthened, with stocks like Haiguang Information and Zhaoyi Innovation also reaching the daily limit [1] - The LiDAR sector saw a significant rise, with Tengjing Technology hitting a 20% limit up [1] - Other notable sectors with strong performance included F5G concept, copper cable high-speed connection, AIPC, and liquid cooling concepts [1] Declining Sectors - Conversely, the precious metals and jewelry sectors declined, with Western Gold leading the drop [1] - The mining sector weakened, with stocks like Tongyuan Petroleum falling over 3% [1] - Reports indicated that Trump is considering strict restrictions on pharmaceuticals from China, leading to a decline in the CRO sector, with stocks like Nuo Si Ge and Tiger Medical leading the losses [1] - The tourism, hotel, outdoor camping, and snow economy sectors also experienced significant declines [1] Stock Performance Rankings - The top-performing sectors included communication equipment (+6.87%), electronic components (+6.50%), and semiconductor (+5.30%) [2] - The brokerage and software sectors also showed positive performance, with increases of +3.15% and +2.859% respectively [2]

人民财讯9月11日电，A股三大指数涨跌不一，沪指跌0.16%，深证成指涨0.11%，创业板指涨0.46%。盘 面上，云计算、CPO、光芯片概念等涨幅居前；CRO、医疗服务、仿制药等板块跌幅居前。 ...

Report Key Points Summary 1. Report Industry Investment Rating No industry investment rating is provided in the content. 2. Report's Core View - From September 1 - 6, 2025, the convertible bond market repaired. Medium - sized varieties gained more attention, while the trading volume proportion of small - sized ones declined, indicating a shift in capital preference. Valuations stretched overall, with the median market price oscillating upwards and remaining at a high level. The implied volatility rose slightly, reflecting increased market optimism [2][6]. - In the industry, power equipment and light manufacturing performed well, while communication and computer sectors faced pressure. Trading was concentrated in electronics, power equipment, and machinery. Individual bonds were still driven by underlying stocks, and some callable bonds achieved high returns. Overall, medium - sized convertible bonds have relative advantages in terms of scale and scarcity. It is advisable to focus on individual bonds with underlying stock support and stable fundamentals, while being vigilant about short - term volatility risks in highly crowded areas [2][6]. 3. Summary by Related Catalogs Market Theme and Style Shift - There may be a trend in the equity market of switching from small - cap to mid - and large - cap indices. Since August 2025, the trading volume proportion of small - cap indices has declined, while that of mid - and large - cap indices has increased. The rolling excess returns of mid - and large - cap indices have also slightly risen since August 2025 [18]. - The attention to medium - sized convertible bonds has increased. The trading volume proportion of medium - and small - sized convertible bond indices shows a significant negative correlation. The proportion of small - sized indices has been in a downward trend since the end of June 2025, and the 12 - week rolling excess return of medium - sized convertible bonds is on the rise, indicating a possible style shift from small - to medium - sized [20]. - Medium - sized convertible bonds currently have relatively low overall scale compared to the previous high of the median market price. With scarcity and a relatively loose market environment, they may be supported to strengthen. Their valuation is in a reasonable range, with the balance - weighted conversion premium rate at the 31.4% quantile since September 2020 and the median premium rate at the 46.4% quantile [22]. Market Weekly Review - **Equity Market**: A - share major indices oscillated and consolidated, with the ChiNext Index rising against the trend. The large - cap sector showed relative resilience. Main funds continued to flow out, but the outflow pressure eased. On Friday, some funds flowed back, indicating market confidence in the future. Industries showed differentiation, with power equipment, non - ferrous metals and other cyclical and resource products strengthening, while AI and military sectors declined. Trading concentration remained high, with funds concentrated in electronics, power equipment, and computer sectors [10]. - **Convertible Bond Market**: The convertible bond market repaired overall, with large - cap varieties rebounding more prominently and small - cap ones relatively under pressure. Market sentiment improved. Valuations stretched overall, with the median market price oscillating upwards and remaining at a high level. The implied volatility rose slightly, reflecting market optimism. Power equipment and light manufacturing led the rise, while communication and computer sectors were relatively weak. Trading activity was concentrated in power equipment, electronics, and machinery. Individual bonds were mainly driven by underlying stocks, and some callable bonds continued to achieve high returns [10]. - **Primary Market**: The primary market supply was stable. There were no new bond listings, but 6 companies updated their issuance plans, indicating sufficient future reserves. In terms of terms, 4 bonds announced potential downward revisions, 4 announced no downward revisions, and 3 proposed downward revisions. In terms of redemptions, 5 bonds were expected to trigger redemptions, 2 announced no early redemptions, and 5 announced early redemptions [10].

Investment Rating - The report maintains a rating of "Buy" for key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others [4][12]. Core Insights - The report indicates that the current industry cycle is expected to continue, driven by improved global liquidity, recovering overseas demand, and technological breakthroughs in areas such as XDC, peptides, and oligonucleotides [6][19]. - In the first half of 2025, the CRO and CDMO sectors showed significant revenue growth, with a 10.4% increase in revenue and a 73.2% increase in net profit attributable to shareholders [6][30]. - The report highlights a divergence in performance between CDMO and CRO, with CDMO experiencing rapid growth while CRO faces slight pressure [6][23]. Summary by Sections Revenue and Profit - In the first half of 2025, the CRO and CDMO sectors achieved a total revenue of 709.1 billion yuan, reflecting a 10.4% year-on-year increase [21]. - The net profit attributable to shareholders reached 151.4 billion yuan, up 73.2%, while the adjusted Non-IFRS net profit was approximately 165.8 billion yuan, marking an 84.8% increase [30][35]. Key Indicators - Demand recovery is evident, with significant increases in orders for major companies such as WuXi AppTec, which reported a 37.2% year-on-year increase in orders [7][37]. - The report notes that the CDMO sector's revenue reached approximately 320.8 billion yuan, a 40.8% increase, while CRO revenue was about 235.9 billion yuan, down 3.5% [23][30]. Focus Companies - The report identifies 30 key companies in the CRO and CDMO sectors, including WuXi AppTec, WuXi Biologics, and others, which are expected to benefit from ongoing industry trends [12][19]. - Specific companies like WuXi Biologics and WuXi AppTec are highlighted for their strong order backlogs and growth potential [38]. Investment Recommendations - The report suggests focusing on CDMO companies due to their expected growth driven by technological advancements and increasing demand for commercialized products [8][19]. - For CRO companies, the report anticipates a gradual recovery as the investment environment improves and orders stabilize [8][19].

Market Overview - The main indices showed slight fluctuations today, with the Shanghai Composite Index increasing by 0.13%, the Shenzhen Component Index rising by 0.38%, and the ChiNext Index up by 1.27% [1] - Among the Shenwan first-level industry performances, the sectors of communication, electronics, and media led the gains, while non-ferrous metals, coal, and steel lagged behind [1] Concept Sector Performance - Overall, the Xinjiang revitalization, CRO, and circuit board concepts performed relatively well, while lithium mining, lithium iron phosphate batteries, and rare metals concepts showed weaker performance [1]

Market Overview - The A-share market showed a positive trend today, with major indices mostly rising. The Shanghai Composite Index increased by 0.46% to close at 3875.53 points, while the Shenzhen Component rose by 1.05% to 12828.95 points. The Sci-Tech 50 index gained 1.18% to reach 1357.15 points, and the ChiNext Index surged by 2.29% to 2956.37 points. Overall, 3206 stocks rose, 2085 fell, and 133 remained unchanged, with a total trading volume of 27.5 billion yuan, a decrease of 483.37 million yuan from the previous trading day [1][2]. Industry Performance - Among the primary industries, telecommunications, comprehensive services, non-ferrous metals, pharmaceutical biology, electronics, and machinery equipment led the gains. Conversely, non-bank financials, banking, household appliances, transportation, automotive, and defense industries experienced declines [1][2]. Sector Highlights - The top-performing concept sectors today included optical modules (CPO), gold and jewelry, optical chips, cobalt mines, advanced packaging, CRO, innovative drugs, optical communications, the SMIC industrial chain, generic drugs, weight loss drugs, high turnover, selected rare metals, germanium-gallium-antimony ink, and semiconductor equipment [2].

Market Overview - The A-share market saw most major indices closing higher today, with the Shanghai Composite Index rising by 0.37% to close at 3857.93 points, the Shenzhen Component Index increasing by 0.99% to 12696.15 points, and the ChiNext Index up by 2.23% to 2890.13 points. However, the Sci-Tech 50 Index fell by 1.71% to 1341.31 points [1][14]. - Overall, there were 1997 stocks that rose and 3305 stocks that fell, with 121 stocks remaining flat. The total trading volume in the Shanghai and Shenzhen markets was 27983 billion yuan, a decrease of 1725 billion yuan compared to the previous trading day [1]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included Comprehensive, Power Equipment, Nonferrous Metals, Food & Beverage, and Pharmaceutical & Biological industries, with respective gains of 3.86%, 3.12%, 2.44%, 2.42%, and 1.42%. Conversely, the sectors that experienced declines included Household Appliances, Transportation, Computer, Communication, and Banking, with losses of 1.82%, 1.69%, 1.48%, 0.80%, and 0.76% respectively [1][14]. Concept Sector Performance - The top-performing concept sectors today included Continuous Board, Rare Earth, Power Battery, Rare Metals, CRO, Lithium Battery, Lithium Iron Phosphate Battery, Lithium Electrolyte, Baijiu, Insurance, Small Metals, New Energy Vehicles, and Beverage Manufacturing [2][11].

Group 1 - The stock price of Jinkai Biotechnology is reported at 42.65 yuan, down 1.15 yuan or 2.63% from the previous trading day, with a trading volume of 3.01 billion yuan and a turnover rate of 12.27% [1] - Jinkai Biotechnology is a global small molecule CDMO service provider focused on custom R&D production services for innovative drug manufacturers, covering process development, optimization, and large-scale production [1] - The company operates in sectors including bioproducts, CRO, and weight loss drugs [1] Group 2 - The semi-annual report disclosed on August 23 shows that the company achieved revenue of 348 million yuan in the first half of the year, a year-on-year increase of 32.98% [1] - The net profit attributable to the parent company reached 71.76 million yuan, representing a year-on-year growth of 123.61% [1] - The net profit excluding non-recurring gains and losses was 59.17 million yuan, up 141.51% year-on-year, with a net cash flow from operating activities of 74.72 million yuan, an increase of 14.47% [1] Group 3 - Today, the net outflow of main funds was 19.71 million yuan, accounting for 0.81% of the circulating market value; over the past five days, the cumulative net outflow of main funds was 709,500 yuan, representing 0.03% of the circulating market value [1]

Market Impact - CRO (未明确公司，需根据上下文补充) 的关注度在 Trump Media 合作声明发布后大幅跃升 853% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 承董事會命 北京昭衍新藥研究中心股份有限公司 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 關於召開2025年半年度業績說明會的公告 (2) 2025年半年度報告 (3) 2025年半年度報告摘要 馮宇霞 董事長 中 國 北 京，2025年8月26日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 ...